Question 12 of 20 Intermediate Practical
How would you silence or enhance effector function by engineering the Fc?
Short answer
Pick a starting subclass that is already close to the behavior you want, then add characterized substitutions. LALA and related variants reduce Fc gamma receptor binding, substitutions such as P329G or K322A remove C1q binding, and afucosylation or Fc variants raise receptor binding when stronger killing is wanted.
Why
Effector function is tuned in two steps: subclass choice and point substitutions. Reviews of IgG engineering tabulate dozens of characterized variants. For silencing, L234A with L235A, known as LALA, reduces Fc gamma receptor binding, and adding P329G gives LALA-PG, which also removes complement engagement.
Residues such as D270, K322, P329 and P331 are critical for C1q binding, so substituting them abolishes complement activation. An IgG2 variant carrying seven substitutions showed no binding to Fc gamma receptors or C1q at all. For enhancement, S239D with I332E and related combinations raise receptor binding, and glycoengineering to remove core fucose raises Fc gamma receptor IIIa affinity without changing the protein sequence.
Each change must be checked rather than assumed. Substitutions can alter thermal stability, create new sequence liabilities, or introduce a new peptide that the immune system may see. Silencing is also never absolute, so a silenced molecule still needs measured binding data for each receptor and for C1q.
How to work it through
- State the mechanism you want and the one you must avoid, receptor by receptor.
- Choose the subclass whose natural profile is closest to that goal.
- Select characterized substitutions from the published engineering literature rather than inventing new ones.
- Express the variants and measure binding to each Fc gamma receptor, to C1q and to FcRn.
- Confirm function in cell-based killing and complement assays with relevant target cells.
- Check stability, aggregation and expression on the final variant before committing.
An example
A team needs an agonist antibody that must not kill the cells it binds. They start from IgG1 for manufacturability and add LALA-PG. Binding assays show Fc gamma receptor I, IIa and IIIa binding reduced to background and no C1q binding, while FcRn binding at pH 6 is unchanged.
A killing assay with donor effector cells shows no lysis against the parental IgG1 control, and the melting temperature drops by under 1 degree C.
Where the answer stops holding
Silencing variants reduce but do not always abolish every interaction, and residual binding can matter at high target density. Engineered sequences may be immunogenic, which only clinical data can settle. In vitro receptor binding does not predict in vivo effect reliably, because receptor expression and immune complex geometry differ.
A strong answer covers
- Choose subclass first, then add characterized substitutions
- LALA and LALA-PG are established silencing variants
- C1q binding depends on residues such as K322, P329 and P331
- Afucosylation enhances receptor IIIa binding without sequence change
- Measure each receptor, C1q and FcRn rather than assuming
Common mistakes
- Calling a variant silenced without measuring each receptor
- Ignoring that Fc substitutions can lower thermal stability
- Assuming aglycosylation is equivalent to targeted silencing substitutions
The interviewer might ask next
How would you show that a silenced Fc still has normal FcRn binding and half-life?